[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prosthetic-valve-endocarditis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prosthetic-valve-endocarditis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100612446","phase-3-adjunctive-rifampin-for-the-treatment-of-prosthetic-valve-endocarditis-due-to-s-aureus-100612446",false,"NCT07253688","Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus","Adjunctive Rifampin for the Treatment of Prosthetic Valve Endocarditis Due to S. Aureus (RIFA-SNAP)","RIFA-SNAP","Inclusion Criteria:\n\n1. Probable or definite prosthetic valve endocarditis involving the tricuspid, pulmonic, mitral and\u002For aortic valves by the 2023 Duke-ISCVID Criteria (including Cardiac PET evidence if applicable);\n2. Patient or healthcare proxy provide informed consent.\n\nExclusion Criteria:\n\n1. Death deemed imminent and inevitable within days or patient will be receiving palliative care and has prognosis \\\u003C 90 days according to the treating team;\n2. Patient requires intensive care but has a do not resuscitate order precluding transfer;\n3. Polymicrobial bacteremia (not including skin commensals or other recognized contaminant);\n4. Organism tests as rifampin resistant;\n5. History of hypersensitivity\u002Fanaphylaxis or severe adverse reaction to rifampin;\n6. Category X or other important drug-drug interaction with rifampin which cannot be safely mitigated \\[with as-needed consultation from experts from pharmacy and\u002For internal medicine\u002Fgeriatrics for potential deprescribing\\];\n7. Child Pugh Class C cirrhosis;\n8. Clinician deems rifampin to be mandatory;\n9. Patient has already received \\>3 days of rifampin at time of screening or \\>10 days of total therapy\n10. Pregnancy or breast feeding\n\nAdministrative exclusions:\n\n1. No reliable means of outpatient contact (telephone\u002Femail\u002Ftext);\n2. Previously enrolled;\n3. Prior S. aureus bacteremia within the preceding 180 days","ALL","18 Years",{"count":20,"type":21},330,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a sub-study of the S. aureus Network Adaptive Platform (SNAP) trial (NCT05137119) wherein we will evaluate whether not giving rifampin in patients with probable or definite prosthetic valve endocarditis due to S. aureus is non-inferior to giving rifampin.",[27,28],"Staphylococcus Aureus Endocarditis","Prosthetic Valve Endocarditis",[30,31,32],"S. aureus bacteremia","Prosthetic valve endocarditis","Rifampin","RECRUITING","2025-12-04",{"date":36,"type":37},"2025-12-10","ACTUAL",{"date":39,"type":37},"2025-11-10",{"date":41,"type":21},"2030-07",{"name":43,"class":44},"Todd C. Lee MD MPH FIDSA","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100515257","evolution-of-pet-fixation-with-fdg-at-the-end-of-antibiotic-treatment-of-infective-endocarditis-on-valvular-prosthesis-100515257","NCT05989152","Evolution of PET Fixation With FDG at the End of Antibiotic Treatment of Infective Endocarditis on Valvular Prosthesis","Evolution of Positron Emission Computed Tomography (PET) Fixation With Fluorodeoxyglucose (FDG) at the End of Antibiotic Treatment of Infective Endocarditis on Valvular Prosthesis","EndEOTEP","\"Inclusion criteria:\n\n* Patient aged 18 or over;\n* Have a prosthetic valve implanted surgically or by catheter for at least 3 months;\n* Presenting a definite IE on a prosthetic valve (ESC definition in force);\n* Having benefited from an FDG-PET examination for diagnostic purposes as part of the treatment revealing pathological hyperuptake at the level of the prosthetic valve AND carried out \\\u003C15 days after the start of antibiotic therapy for infective endocarditis;\n* Absence of cardiac surgical intervention performed for the current episode of AE or planned before the end-of-treatment FDG-PET\n\nExclusion criteria:\n\n* Patient under legal protection, guardianship or curators;\n* Pregnancy, breastfeeding;\n* Patient not affiliated to a health insurance scheme or not a beneficiary of a social security scheme;\n* Simultaneous participation in a study on FDG-PET;\n* Absence of informed consent signed by the patient.\"",{"count":55,"type":21},50,[57],"NA","In patients with prosthetic valve endocarditis (PVE) and pathological valvular FDG uptake on the initial FDG-PET and not referred to valve replacement at the acute phase, the study will assess whether FDG-PET is able to identify those at increased risk of PVE relapse.",[28],[61,62,63],"Infective endocarditis","end of treatment","Positron emission tomography","2025-07-31",{"date":66,"type":37},"2025-08-05",{"date":68,"type":37},"2025-04-17",{"date":70,"type":21},"2027-12",{"name":72,"class":44},"Assistance Publique - Hôpitaux de Paris"]